Toyota|$17.87 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.62 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.98 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$514.47 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.97 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.11 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.46 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.41 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.65 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.66 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.42 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.70 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.51 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$466.70 (¥73,850)-2.29%▼ (in JPY terms)
Toyota|$17.87 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.62 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.98 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$514.47 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.97 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.11 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.46 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.41 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.65 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.66 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.42 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.70 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.51 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$466.70 (¥73,850)-2.29%▼ (in JPY terms)

JP3188220002

2026-08-04 Otsuka Holdings Co.,Ltd. “VOYXACT® (sibeprenelimab), a treatment for IgA nephropathy, has released 2-year eGFR (estimated glomerular filtration rate) data from a Phase 3 trial – demonstrating the potential to stabilize the rate of kidney function decline within the age-appropriate range and fundamentally alter disease progression.”

by

2026-08-04 Otsuka Holdings Co.,Ltd. “VOYXACT® (sibeprenelimab), a treatment for IgA nephropathy, has rel … 続きを読む

2026-08-03 Otsuka Holdings Co.,Ltd. “Fujifilm and Taiho Pharmaceutical have entered into a strategic partnership to develop next-generation antibody-drug conjugate (ADC) manufacturing technology. The goal is to achieve stable production of high-quality ADCs by optimizing the manufacturing process.”

by

2026-08-03 Otsuka Holdings Co.,Ltd. “Fujifilm and Taiho Pharmaceutical have entered into a strategic par … 続きを読む

2026-07-27 Otsuka Holdings Co.,Ltd. “Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026 (Link to Otsuka America Pharmaceutical's English page).”

by

2026-07-27 Otsuka Holdings Co.,Ltd. “Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VI … 続きを読む

Contact